Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 143Neoplasm Metastasis 16Ovarian Neoplasms 6Advanced Breast Cancer 6Prostatic Neoplasms 5Breast Cancer Metastatic 5Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Lobular 3Lung Neoplasms 2HER2-positive Breast Cancer 2Exanthema 2Estrogen Receptor-positive Breast Cancer 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1The Neoadjuvant Therapy 1Stomach Neoplasms 1Solid Tumor 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Sarcoma 1Salivary Gland Neoplasms 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Malignant Neoplasms of Female Genital Organs 1

Interventions

capivasertib 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × CCCA Assessed by Ki67 Drop Below <2.7% From Baseline × Fulvestrant × Clear all
NCT06607757 2025-04-02

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

GBG Forschungs GmbH

Phase 2 Recruiting
120 enrolled

CCCA Assessed by Ki67 Drop Below <2.7% From Baseline

Data powered by HemOnc (CC BY 4.0) Colophon âš¡